Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis is a section of the Elsevier journal family Mutation Research, published in Amsterdam, and it carries the parent title from 1964, when that journal was founded. Its 2025 Journal Impact Factor is 2.4.《突变研究（诱变基础与分子机制）》是 Elsevier 旗下 Mutation Research 系列的一个分册，在阿姆斯特丹出版，沿用母刊 1964 年创刊时的题名。其 2025 年期刊影响因子为 2.4。

Scope

• The scope statement promises coverage of every aspect of DNA mutation and epimutation, running from basic evolutionary questions to genetic and epigenetic diagnosis and treatment.范围说明承诺覆盖 DNA 突变与表观突变的全部方面，从基础演化问题一直延伸到遗传与表观遗传的诊断和治疗。

• Mutation itself is read broadly, taking in point mutations, structural variation across whole genomes, chromosome aberrations and aneuploidy of every size. No single scale of change is favored.其中突变一词取宽泛口径，涵盖点突变、全基因组范围内的结构变异、染色体畸变以及各种尺度的非整倍体。变化发生的尺度并不作限定。

• Epimutation is defined by its carriers instead, namely DNA methylation, histone modification and the small regulatory RNAs that act on chromatin. Each one alters expression without touching the base sequence.表观突变则按其载体界定，即 DNA 甲基化、组蛋白修饰以及作用于染色质的小调控 RNA。三者改变的是表达，碱基序列本身不动。

• One cluster of interests concerns DNA damage and mutation as they bear on development, differentiation, stem cell biology and cell fate, with cell death and cell senescence included.一类关注点落在 DNA 损伤与突变对发育、分化、干细胞生物学与细胞命运的影响，细胞死亡与细胞衰老都在其中。

• Human molecular epidemiology is another, with genome instability traced through to complex phenotypes, to disease risk within populations and to the causal chains that join them.人类分子流行病学是另一条主线，基因组不稳定被一路追踪到复杂表型、人群中的疾病风险以及连接两者的因果链条。

• Mechanisms come next, specifically the ways mutation and epimutation are induced during DNA repair, replication and recombination, including the errors those pathways make themselves.机制层面的问题紧随其后，具体指 DNA 修复、复制与重组过程中突变与表观突变如何被诱发，也包括这些通路自身造成的错误。

• Detection is treated as a research area of its own, with ultra-high-throughput sequencing named as the priority among new methods, alongside the analysis such data demand.检测方法被当作独立的研究方向，超高通量测序被点名为新方法中的重点，随之而来的数据分析也在其列。

• Somatic mutation and epimutation profiles in cancer and in ageing form a further theme, one that has widened along with sequencing capacity. The two conditions are handled side by side.癌症与衰老中的体细胞突变和表观突变图谱构成又一个主题，这一主题随测序能力的提高而扩展。这两种情形被放在同一框架下讨论。

• De novo mutation and its part in human disease and ageing are set beside mutation as it is distributed across populations in genomic studies.新发突变在人类疾病与衰老中的作用，与群体基因组学中突变的分布状况并列陈述。

• The interplay between mutation and epimutation gets a heading of its own, as does the part epimutation plays in chromatin structure and function. Neither is treated as a subordinate topic.突变与表观突变之间的相互作用单列一条，表观突变在染色质结构与功能中的作用同样单列。两者都不作为附属议题处理。

• Mitochondrial DNA mutation is named separately, together with its consequences for disease and for the ageing organism, so the organelle genome is not folded into the nuclear story.线粒体 DNA 突变单独列出，连同它在疾病与衰老机体中的后果一并讨论，细胞器基因组并未并入核基因组的叙述。

• Methods for generating mutation and epimutation in cell lines and in animal models close the list, which keeps experimental design and model building inside the scope.在细胞系与动物模型中生成突变与表观突变的新方法收束了这份清单，实验设计与模型构建因此留在范围之内。

• Research papers carry the bulk of the content, while short communications are held to five printed pages and are expected to make a single point.研究论文承担了刊物的主要篇幅，短通讯以 5 个印刷页为限，只陈述单一要点。

• Rapids are accelerated at editorial discretion and appear within eight to ten weeks of acceptance, while current issues, short topical pieces of one or two pages, follow within ten weeks.快速通道稿件由编辑判断是否加速，接收后 8 至 10 周内发表，时事短评则是 1 至 2 页的主题短论，接收后 10 周内刊出。

• Mini-reviews stay under ten printed pages and normally cite work from the past two years only, and unsolicited reviews must argue their novelty first.小型综述不超过 10 个印刷页，参考文献一般只取近两年，非约稿综述须先论证其新颖性。

History

• Volume 1 of Mutation Research appeared in 1964 under the Elsevier imprint, and the series has been issued by the same house ever since.母刊 Mutation Research 的第 1 卷于 1964 年在 Elsevier 名下问世，此后一直由这家出版机构发行。

• NLM gives 1964 as the first year and opens its indexing at volume 2, number 1, dated February 1965, which fixes volume 1 in 1964.NLM 将 1964 年记为首年，索引起点是 1965 年 2 月的第 2 卷第 1 期，据此可定第 1 卷属于 1964 年。

• That first title served the whole field on its own. A section structure came later, and the family now holds four sections.最初那份刊物独自覆盖整个领域。分册结构是后来才有的，如今该系列共含四个分册。

• The other three are DNA Repair, Genetic Toxicology and Environmental Mutagenesis, and Reviews, which between them cover repair, toxicology and review material.其余三个分别是 DNA Repair、Genetic Toxicology and Environmental Mutagenesis 与 Reviews，分别对应修复、毒理与综述类内容。

• The present section keeps the parent title and the parent's original serial numbers, so nothing in the masthead signals a break with the older volumes.本分册沿用母刊的题名与最初的刊号，刊头因此看不出与旧卷之间存在断点。

• Its banner reads A section of Mutation Research and Formerly known as Mutation Research, two labels that settle the relationship without dating it.刊头同时写着「A section of Mutation Research」与「Formerly known as Mutation Research」，两行标签点明归属，却未标注改动年份。

• Two sets of identifiers now run in parallel. The publisher page lists a Linking ISSN of 1386-1964 and an Online ISSN of 1879-2871, and recent Crossref deposits carry 1386-1964.两套标识号如今并行使用。出版社页面列出 Linking ISSN 1386-1964 与 Online ISSN 1879-2871，近年 Crossref 存档也多落在这组号上。

• Journal Citation Reports and NLM still use 0027-5107 and 1873-135X, the pair that has followed this title since 1964. Both numbers reach the same back file.Journal Citation Reports 与 NLM 仍沿用 0027-5107 与 1873-135X，这对号码自 1964 年起一直跟随该题名。两个号码指向同一批过刊。

• The schedule is continuous publication in two volumes a year with no issue numbers, so volumes 830 and 831 cover 2025 and volumes 832 and 833 cover 2026.刊期为每年两卷、连续出版、不设期号，第 830 与 831 卷对应 2025 年，第 832 与 833 卷对应 2026 年。

• NLM still records a monthly frequency dated 2014, a value that predates the present arrangement of two open volumes each year. Its main-title field still reads Mutation research.NLM 至今仍标注 2014 年起的月刊频率，这一取值早于现行的每年两卷安排。其主标题栏著录的仍是母刊名 Mutation research。

• Publication is hybrid. Library subscriptions pay for access, authors may buy open access, and gold open access accounts for 13.41 per cent of the content.出版走混合模式。订阅阅读由图书馆付费，作者可选择开放获取，金色开放获取占全部内容的 13.41%。

• The five-year Journal Impact Factor stands at 2.2 and the Journal Citation Indicator at 0.52, the 44.5th percentile of its field. The 2022 impact factor was 3.151, against 2.4 for 2025.五年影响因子为 2.2，期刊引文指标为 0.52，百分位 44.5。2022 年的影响因子为 3.151，2025 年为 2.4。

• Three JCR categories list it in the third quartile, at 122 of 180 in biotechnology and applied microbiology, 107 of 192 in genetics and heredity and 74 of 106 in toxicology.Journal Citation Reports 的三个类目都把该刊列在第三四分位，生物技术与应用微生物学 180 种中排 122，遗传学与遗传 192 种中排 107，毒理学 106 种中排 74。

• Citations total 4,485 against 28 articles a year, the cited half-life reaches 18.9 years, and MEDLINE has covered the title from February 1965, with PubMed and Index Medicus running alongside.总被引 4485 次，年发文 28 篇，被引半衰期达 18.9 年，MEDLINE 自 1965 年 2 月起收录该刊，PubMed 与 Index Medicus 同期并行。

Editors

• Two editors in chief share the chair. Vanesa Gottifredi works at the Leloir Institute in Argentina and studies DNA replication, translesion synthesis and replication stress.主编一职由两位学者共同担任。（Vanesa Gottifredi）任职于阿根廷的 Leloir Institute，研究方向为 DNA 复制、跨损伤合成与复制压力。

• Her counterpart Karen M. Vasquez works in pharmacology and toxicology at The University of Texas at Austin, on recombination, DNA structure, nucleotide excision repair, DNA methylation and cancer biology.另一位主编（Karen M. Vasquez）任职于美国 The University of Texas at Austin 的药理学与毒理学部，研究重组、DNA 结构、核苷酸切除修复、DNA 甲基化与癌症生物学。

• Four associate editors share the handling load, which keeps decisions inside a small group. Giovanna Damia works at the Mario Negri Institute for Pharmacological Research in Milan, Italy.四位副编辑分担稿件审理，决定权因此集中在少数人手里。（Giovanna Damia）任职于意大利米兰的 Mario Negri Institute for Pharmacological Research。

• The others are Nayun Kim of the University of Texas at Austin College of Pharmacy, Yuan Liu of Florida International University and Nadja de Souza-Pinto of the University of Sao Paulo.其余三位分别是 The University of Texas at Austin 药学院的（Nayun Kim）、Florida International University 的（Yuan Liu）与 University of Sao Paulo 生物化学系的（Nadja de Souza-Pinto）。

• Frits Sobels is recorded as founding editor, a line kept apart from the two current chairs, and three editors emeritus are named, Leon H.F. Mullenders, Peter J. Stambrook and Jan Vijg.创刊主编记为（Frits Sobels），这一行与现任两位主编分列，另有三位荣休编辑在列，即（Leon H.F. Mullenders）、（Peter J. Stambrook）与（Jan Vijg）。

• Editors and board members number 36 in all and come from 9 countries or territories, with 25 in the United States, 2 in Brazil and 2 in Canada.编辑与编委合计 36 人，来自 9 个国家或地区，其中美国 25 人，巴西 2 人，加拿大 2 人。

• Review is single anonymized, so reviewers see author names and authors do not learn theirs. An editor screens each submission first, and manuscripts that pass go to at least two reviewers.评审采用单匿名方式，审稿人看得到作者姓名，作者却不知道审稿人是谁。编辑先行初筛，通过的稿件一般至少送两位审稿人评审。

• One appeal is allowed per manuscript, and an editor with a conflict of interest steps away from the decision, which passes to a colleague.每篇稿件可申诉一次，与稿件存在利益冲突的编辑不参与相关决定，该稿改由其他编辑处理。

• Submissions go through Editorial Manager, abstracts stop at 250 words, and keywords run from one to seven. Three to five highlights of no more than 85 characters each are required.稿件经 Editorial Manager 投递，摘要不超过 250 词，关键词 1 至 7 个，另须提交 3 至 5 条不超过 85 字符的亮点说明。

• A graphical abstract is encouraged, and research data are declared under the Option C statement that the guide sets out item by item. Highlights are required, not optional.刊物鼓励提供图形摘要，研究数据按 Elsevier 的 Option C 声明，作者指南对各项要求逐条列出。亮点说明属必备项，并非可选项。

• Unsolicited reviews have to argue their novelty in the cover letter and show, paper by paper, what the authors know of the literature. Mini-reviews that arrive uninvited follow the same rule.非约稿综述须在投稿信中论证其新颖性，并逐篇说明作者对该文献的掌握程度。未经约稿的小型综述同样适用这一条。

• The journal states that it follows the general direction of the IAEMGS member societies, thirteen of which are named, among them CEMS, EEMGS, EMGS, JEMS and TEMS.该刊声明遵循 IAEMGS 各成员学会的总体方向，官网点名其中 13 个学会，CEMS 与 EEMGS 等均在其列。